Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07247110 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
A Phase 1 study of Malignant Neoplasm, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 9
- Study locations
NCT07247110: Recruiting Phase 1 study of Malignant Neoplasm, sponsored by Merck Sharp & Dohme.
NCT07247110 is a Phase 1 study of Malignant Neoplasm that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 250 participants, below the 509-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (51% lower). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07247110, a Phase 1 study of Malignant Neoplasm, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 9
- Study locations
Study Summary
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
Primary Outcome
A DLT is defined as the occurrence of protocol-specified toxicities, unless clearly related to disease progression or intercurrent illness.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Cetuximab
- DRUG MK-4716
Study Locations (9)
Other
- Rambam Health Care Campus ( Site 0252) - Haifa
- Rabin Medical Center ( Site 0253) - Petah Tikva
- Sheba Medical Center ( Site 0251) - Ramat Gan
- Hospital General Universitari Vall d Hebron ( Site 0360) - Barcelona
- Hospital Clinic de Barcelona ( Site 0362) - Barcelona
- Hospital Universitario Fundacion Jimenez Diaz ( Site 0361) - Madrid
Texas
- NEXT Oncology ( Site 0051) - Irving
Virginia
- NEXT Virginia ( Site 0054) - Fairfax
Western Australia
- One Clinical Research ( Site 0454) - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 1 |
What NCT07247110 shows while recruiting
NCT07247110 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 509-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT07247110 lists 9 locations in 4 states (Other, Texas, Virginia).
Frequently Asked Questions
What is clinical trial NCT07247110 about?
NCT07247110 is a clinical study titled "A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)". Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
What is the current status of trial NCT07247110?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2025-12-16. Estimated completion is 2030-12-01.
What conditions does trial NCT07247110 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT07247110?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cetuximab (BIOLOGICAL), MK-4716 (DRUG).
Who is sponsoring clinical trial NCT07247110?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07247110 being conducted?
This trial has 9 study locations across Texas, Virginia, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07247110's enrollment target sits among peer trials
250 18th of 59 higher than 41 of 59 other Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
-
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
RECRUITING · Phase 1
-
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI